Hodges Capital Management Inc. Buys New Position in SOPHiA GENETICS SA $SOPH

Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH) during the first quarter, Holdings Channel.com reports. The fund bought 435,836 shares of the company’s stock, valued at approximately $2,157,000.

Other institutional investors also recently added to or reduced their stakes in the company. Perkins Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS in the third quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter worth $50,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter worth $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter worth $55,000. 31.59% of the stock is owned by institutional investors.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.50, for a total value of $27,500.00. Following the transaction, the insider owned 240,780 shares of the company’s stock, valued at approximately $1,324,290. The trade was a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 6,944 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $5.51, for a total value of $38,261.44. Following the completion of the transaction, the chief technology officer directly owned 197,456 shares in the company, valued at approximately $1,087,982.56. This represents a 3.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 228,677 shares of company stock worth $1,173,913. 4.88% of the stock is currently owned by insiders.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $5.25 on Tuesday. SOPHiA GENETICS SA has a 1-year low of $2.92 and a 1-year high of $6.30. The company has a 50 day moving average of $5.12 and a 200-day moving average of $4.96. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The firm has a market cap of $440.84 million, a price-to-earnings ratio of -10.09 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Analyst Ratings Changes

SOPH has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.